Aptamer Group, the developer of next-generation synthetic binders for the life sciences, entered a new contract valued at up to £617,000 with a top-five pharmaceutical company. The expanded ...

Across biomedical research and drug development, the boundaries of possibility are shifting. Scientists are uncovering new disease mechanisms, redefining diagnostic strategies, and designing ...

The enzymatic DNA synthesis market is on the cusp of extraordinary expansion. Forecasts indicate that the market will grow from USD 371 million in 2025 to nearly USD 3,938.9 million by 2035, marking ...

Cost-effective oligo system design schematic. Each synthetic oligo consists of two oligos (oligo-A and oligo-B), one forward primer (Primer-A), and two reverse primers (Primer-B and Primer-C). (A) ...

Aptamer Group plc, a developer of next-generation synthetic binders for the life sciences industry, has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology ...

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announced the launch of its biomarker discovery service, ...

The synthetic biology market is growing considerably as a result of adoption of advanced technologies in genetic engineering, bioinformatics, and bio manufacturing. New technologies such as ...

FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation resulted from combining oligonucleotides with ...

Novartis will pay $800 million upfront to acquire Regulus Therapeutics, a San Diego biotechnology company that launched nearly two decades ago with plans to make drugs capable of targeting small ...

C.B.S. Scientific's new high-visibility mini horizontal gel system simplifies the separation and identification of DNA and RNA fragments, PCR products, and synthetic oligonucleotides. The mini gel ...